Transgene Biotek inks MoU with Armour Therapeutics

27 Apr 2012 Evaluate

Transgene Biotek, one of India’s earliest biotechnology company, signalled its continued westward expansion with the signing of a Memorandum-of-Understanding (MoU) with Armour Therapeutics Inc. (Armour) of Toronto, Canada. Transgene and Armour are exploring a strategic relationship to co-develop Armour’s drug candidates for reproductive cancers. Armour’s lead anti-relax-in molecule, AT- 001, is being developed to treat hormone refractory prostate cancer.

The newly signed MoU with Armour potentially paves the way for a strategic relationship between the two companies, unlocking scientific and operational synergies, providing Transgene with another presence in the West giving it better access to more seasoned investors and strategic partners, and enabling Armour access to novel drug delivery technologies.

As a further signal of Transgene’s long term strategic geographical focus, the company has recently engaged HealthProBioVentures LLC, a New York based registered investment bank and strategic advisory firm that specializes in the life sciences industry.

Transgene Biotek Share Price

7.07 0.14 (2.02%)
01-Nov-2024 18:59 View Price Chart
Peers
Company Name CMP
Apollo Hospital Ent. 7036.65
Max Healthcare Inst 1006.75
Narayana Hrudayalay 1249.35
Aster DM Healthcare 444.55
Global Health 1115.50
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.